Displaying drugs 601 - 625 of 11746 in total
Human interferon beta
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … significantly debilitating with a profound impact on the quality of life. ... Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis ... It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity. …
Satralizumab
Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... [L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare ... "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a …
Indacaterol
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …
Adalimumab
Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available ... It is produced by recombinant DNA technology using a mammalian cell expression system. ... Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid …
Alclofenac
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Description: … Alclofenac is a non-steroidal anti-inflammatory drug. …
Apronalide
Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved
Atracurium
Approved
Experimental
Investigational
Remestemcel-L
Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … risk for poor outcomes and creating a significant clinical challenge [A31818]. ... Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal ... aGvHD is a T-cell mediated disease that occurs after allogeneic hematopoietic stem cell transplant and …
Fenofibric acid
Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia …
Methyldopa
Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading...
Approved
Matched Description: … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. ... [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug …
Crotalus adamanteus antivenin
Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 .
The eastern diamondback...
Approved
Experimental
Zopiclone
Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Description: … Zopiclone is a novel hypnotic agent used in the treatment of insomnia. …
Methysergide
An ergot derivative that is a congener of lysergic acid diethylamide. It antagonizes the effects of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the properties of other ergot alkaloids. Methysergide is used prophylactically in migraine and other vascular headaches and to antagonize serotonin in the...
Approved
Matched Description: … An ergot derivative that is a congener of lysergic acid diethylamide. …
Methoxy polyethylene glycol-epoetin beta
Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Description: … (ESA) with a longer half-life than erythropoietin. ... Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Iothalamic acid
Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
Approved
Matched Description: … Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Matched Categories: … Compounds used in a research, industrial, or household setting …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... the first therapeutic option for patients with MoCD type A. ... Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a …
Ivosidenib
Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. ... The drug is only effective in patients with a susceptible IDH1 mutation. ... L48781]
In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Corynebacterium diphtheriae
Corynebacterium diphtheriae toxin is extracted from the pathogenic actinobacterium C. diphtheriae that causes diphtheria. The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered. The vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children.
Approved
Investigational
Matched Description: … The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with …
Paroxetine
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline...
Approved
Investigational
Matched Description: … Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. ... It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic ... [L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition …
Chloroprocaine
Chloroprocaine is an ester local anesthetic commonly available in its salt form, chloroprocaine hydrochloride. Similar to other local anesthetics, it increases the threshold for electrical excitation in nerves by slowing the propagation of the nerve impulse and reducing the rate of rise of the action potential. The pharmacological profile of...
Approved
Investigational
Matched Description: … [L43402] The pharmacological profile of chloroprocaine is characterized by a short latency and duration ... Chloroprocaine can be given as an injection, and is available in formulations with and without methylparaben as a …
Ambrosia artemisiifolia pollen
Ambrosia artemisiifolia pollen is the pollen of the Ambrosia artemisiifolia plant. Ambrosia artemisiifolia pollen is mainly used in allergenic testing.
Approved
Viltolarsen
Duchenne muscular dystrophy (DMD) is an X-linked recessive allelic disorder characterized by a lack of functional dystrophin protein, which leads to progressive ambulatory, pulmonary, and cardiac function and is invariably fatal. A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by...
Approved
Investigational
Matched Description: … Viltolarsen was developed by Nippon Shinyaku Co LTD and is being marketed under the name VILTEPSO™. ... A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) ... links between nucleotides are replaced with a phosphorodiamidate linkage. …
Levomilnacipran
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate milnacipran.[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved...
Approved
Investigational
Matched Description: … a more potent inhibitor of norepinephrine reuptake than serotonin reuptake. ... Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is ... [L47956] While levomilnacipran was previously investigated and proposed as a potential treatment for …
Thonzonium
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. …
Clemastine
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
Approved
Investigational
Displaying drugs 601 - 625 of 11746 in total